Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN 70 30 PEN versus HUMULIN R PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN 70 30 PEN versus HUMULIN R PEN.
HUMULIN 70/30 PEN vs HUMULIN R PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro and insulin lispro protamine suspension. Insulin lispro lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production. Insulin lispro protamine provides intermediate-acting basal coverage.
Insulin is a hormone produced by the pancreas that regulates glucose metabolism. Exogenous insulin replaces endogenous insulin, binding to insulin receptors on cell surfaces, activating tyrosine kinase activity, and promoting glucose uptake, glycogen synthesis, and lipogenesis while inhibiting gluconeogenesis and lipolysis.
Subcutaneous injection, individualized based on metabolic needs and blood glucose monitoring; typical starting dose for type 1 diabetes: 0.5 to 0.6 units/kg/day in divided doses (usually twice daily with 70% intermediate-acting NPH and 30% regular insulin); for type 2 diabetes: 0.2 units/kg/day initially, adjusted per glycemic response.
Subcutaneous injection, usual starting dose 0.2 to 0.4 units/kg/day divided into two or more injections; total daily insulin requirements may range from 0.5 to 1.0 units/kg/day.
None Documented
None Documented
The terminal elimination half-life of insulin in Humulin 70/30 is approximately 1.5 hours for the regular insulin component and 4-6 hours for the NPH component due to protamine suspension, resulting in a prolonged duration of action.
Intravenous: plasma half-life is ~5-10 minutes (distribution) and elimination half-life ~1.5-2 hours (reflecting clearance from peripheral compartments). Subcutaneous: prolonged due to absorption rate-limited kinetics; terminal half-life ~5-10 hours.
Insulin is primarily eliminated via renal metabolism and excretion; approximately 30-80% is cleared by the kidneys, with the remainder undergoing hepatic metabolism. Biliary/fecal excretion is negligible (<1%).
Primarily renal (hepatic metabolism to inactive metabolites accounts for <20%); ~30-80% of dose excreted unchanged in urine via glomerular filtration.
Category C
Category C
Human Insulin
Human Insulin